You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》瑞信:藥明生物(02269.HK)中期業績令人驚喜 料可推動股價表現
阿思達克 07-20 11:10
藥明生物(02269.HK)今早股價抽上,一度彈高近5.8%,最新上揚近4.8%報81.25元。就藥明生物昨發今年上半年盈喜,預期上半年錄得收益按年增長61%至63%;公司利潤按年增長36%至38%,並料公司非國際財務報告準則經調整純利將增長58%至60%。瑞信發表報告表示藥明生物今年上半年收入及盈利均優於市場預期,料可推動股價表現。 該行指,重申對藥明生物「跑贏大市」評級及目標價110元。該行藥明生物今年上半年業務增長表明其整體業務相當穩健,能夠抵禦像今年第二季疫情的封鎖所造成的中斷影響。 瑞信預計藥明生物其兩家子公司,或在今年之前從美國商務部「未經核實」實體名單(Unverified List)中移除,因為美國相關工作人員已經到訪相關公司的設施。(wl/k) ~
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account